Skip to content
value.today

Opus Genetics, Inc.

IRD
$396 Mmarket cap on Oct 15, 2026
1D
-3.3%
Compare
World rank
#13,589
Revenue
$14 M
For year ending December-2025
Net income
$-50 M
-349.2% margin
SEC filing
Employees
27
As of December 31, 2025
value.today research

Opus Genetics, Inc. in brief

Opus Genetics, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $396 M on 15 October 2026, which makes it the 13,589th largest listed company in the world and the 2,674th largest in the USA on this site. In the year to December 2025 it had sales of $14 M and a net loss of $50 M. It employs about 27 people. Its shares trade under the symbol IRD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, and other types of therapies for additional ophthalmic disorders.

In November 2020, Ocuphire Pharma, Inc. completed a reverse merger into Rexahn Pharmaceuticals, Inc., a publicly traded company that had ceased its business of drug development activities, and simultaneously raised just over $21 million through an offering of common shares and warrants to purchase common shares. The combined company continued to operate under the name of Ocuphire Pharma, Inc.

Opus Genetics, Inc. timeline

6 events, 2003–2024
  1. 2003
  2. ✎
    Renamed Corporate Road Show Dot Com Inc
    Formerly Ferraro Frank.
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2005
  5. ✎
    Renamed Rexahn Pharmaceuticals, Inc.
    Formerly Corporate Road Show Dot Com Inc.
  6. 2020
  7. ✎
    Renamed Ocuphire Pharma, Inc.
    Formerly Rexahn Pharmaceuticals, Inc..
  8. 2022
  9. 💰
    Record revenue of $40 million
    FY2022, the highest of the 6 years on record.
  10. 2024
  11. ✎
    Renamed Opus Genetics, Inc.
    Formerly Ocuphire Pharma, Inc..

Events of Opus Genetics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$111 M$221 M$332 M$443 M2020202120222023202420252026

World rank over time

▲ up 13,215 places since 2020
2020-01-01: #26832#26,83220202026-10-14: #13552#13,55220262026-10-15: #13617#13,6172026

Rank in USA: #4,723 (Jan 2020) · #2,668 (Oct 2026) · #2,677 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
50.0×
Price / book
25.8×
Free cash flow yield
-1.7%
Net margin (TTM)
-1723.5%
Operating margin
-271.8%
Return on equity
-890.4%
Liabilities / assets
69.5%
Net debt
$-44M
Revenue growth
+29.2%
R&D / revenue
217.0%
Revenue per employee
$526 K
Profit per employee
$-1.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-14M—FY18Fiscal year ending Dec 2019: revenue $3M, net income $-6M$3MFY19Fiscal year ending Dec 2020: revenue —, net income $-25M—FY20Fiscal year ending Dec 2021: revenue $1M, net income $-57M$1MFY21Fiscal year ending Dec 2022: revenue $40M, net income $18M$40MFY22Fiscal year ending Dec 2023: revenue $19M, net income $-10M$19MFY23Fiscal year ending Dec 2024: revenue $11M, net income $-58M$11MFY24Fiscal year ending Dec 2025: revenue $14M, net income $-50M$14MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$14M+29.2%$-39M$-50M-349.2%
Dec 2024$11M-42.3%$-62M$-58M-523.5%
Dec 2023$19M-52.2%$-11M$-10M-52.4%
Dec 2022$40M+6654.2%$18M$18M44.9%
Dec 2021$1M—$-23M$-57M-9608.5%
Dec 2020——$-20M$-25M—
Dec 2019$3M—$-4M$-6M-205.7%
Dec 2018——$-21M$-14M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-35M——$-0.80—
Dec 2024$-26M——$-2.15—
Dec 2023$-1M——$-0.46—
Dec 2022$14M——$0.87—
Dec 2021$-19M——$-3.82—
Dec 2020$-7M$0M$-7M$-5.28—
Dec 2019$-4M$0M$-4M$-2.17—
Dec 2018$-19M——$-5.25—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$8M
Net income, trailing 12 months
$-137M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $4M, net income $-35M$4MDec ’24Three months to Mar 2025: revenue $4M, net income $-8M$4MMar ’25Three months to Jun 2025: revenue $3M, net income $-7M$3MJun ’25Three months to Sep 2025: revenue $3M, net income $-17M$3MSep ’25Three months to Dec 2025 (from the annual report): revenue $4M, net income $-17M$4MDec ’25Three months to Mar 2026: revenue $2M, net income $-66M$2MMar ’26Three months to Jun 2026: revenue $1M, net income $-8M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $-47M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-63.0% on a year earlier), net income $-47M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Opus Genetics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$14 M
Operating income
$-39 M
Net income
$-50 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$50 M
Total liabilities
$35 M
Total equity
$15 M

As of December-2025

Top 100 institutional investors in Opus Genetics, Inc.#

As of Sep 30, 2026
114 institutions held 77.8 M shares (about 80.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.3%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Opus Genetics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Perceptive Advisors LLC9,000,000New9.31%$44 MNov 16, 2026
2Caligan Partners LP5,960,972-116,112 (-1.91%)6.17%$29 MNov 16, 2026
3Cormorant Asset Management, LP5,500,000New5.69%$27 MNov 16, 2026
4BlackRock, Inc.5,236,178+2,119,691 (+68.02%)5.42%$25 MNov 13, 2026
5Nantahala Capital Management, LLC4,569,528-1,553,190 (-25.37%)4.73%$22 MNov 13, 2026
6Boxer Capital Management, LLC4,533,660+1,718,660 (+61.05%)4.69%$22 MNov 16, 2026
7Balyasny Asset Management L.P.3,728,638+640,772 (+20.75%)3.86%$18 MNov 16, 2026
8BIOS Capital Management, LP3,683,4290 (0.00%)3.81%$18 MNov 13, 2026
9Vanguard Capital Management LLC3,273,451+314,768 (+10.64%)3.39%$16 MNov 13, 2026
10Marshall Wace, LLP3,161,606+1,215,997 (+62.50%)3.27%$15 MNov 13, 2026
11Millennium Management LLC3,136,021+833,920 (+36.22%)3.24%$15 MNov 16, 2026
12Trails Edge Capital Partners, LP2,411,657-332,001 (-12.10%)2.50%$12 MNov 16, 2026
13Adage Capital Partners GP, L.L.C.2,254,996-3,774,779 (-62.60%)2.33%$11 MNov 16, 2026
14Geode Capital Management, LLC1,810,968+443,256 (+32.41%)1.87%$9 MNov 6, 2026
15ADAR1 Capital Management, LLC1,783,7810 (0.00%)1.85%$9 MNov 16, 2026
16State Street Corp1,330,398+540,262 (+68.38%)1.38%$6 MNov 12, 2026
17Boothbay Fund Management, LLC1,166,787-22,728 (-1.91%)1.21%$6 MNov 16, 2026
18AWM Investment Company, Inc.1,051,936+819,346 (+352.27%)1.09%$5 MNov 13, 2026
19Logos Global Management LP1,000,000New1.03%$5 MNov 16, 2026
20Blue Owl Capital Holdings LP969,605New1.00%$5 MNov 13, 2026
21Affinity Asset Advisors, LLC900,000New0.93%$4 MNov 13, 2026
22Goldman Sachs Group Inc877,876-649,353 (-42.52%)0.91%$4 MNov 16, 2026
23Great Point Partners LLC776,881-1,193,306 (-60.57%)0.80%$4 MNov 16, 2026
24Opaleye Management Inc.750,000-375,000 (-33.33%)0.78%$4 MNov 16, 2026
25Vanguard Portfolio Management LLC734,419+362,469 (+97.45%)0.76%$4 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Opus Genetics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26UBS Group AG723,459+39,564 (+5.79%)0.75%$4 MNov 10, 2026
27Woodline Partners LP661,729-772,984 (-53.88%)0.68%$3 MNov 16, 2026
28Northern Trust Corp560,304+118,150 (+26.72%)0.58%$3 MNov 16, 2026
29Vanguard Fiduciary Trust Co538,986+128,611 (+31.34%)0.56%$3 MNov 13, 2026
30Acuta Capital Partners, LLC514,110New0.53%$2 MNov 16, 2026
31Citadel Advisors LLC497,481-168,181 (-25.27%)0.51%$2 MNov 16, 2026
32Squarepoint Ops LLC352,924+22,141 (+6.69%)0.37%$2 MNov 9, 2026
33Susquehanna International Group, LLP350,141+153,244 (+77.83%)0.36%$2 MNov 16, 2026
34XTX Topco Ltd287,409+143,314 (+99.46%)0.30%$1 MNov 16, 2026
35Propel Bio Management, LLC270,036New0.28%$1 MNov 13, 2026
36Aureus Asset Management, LLC265,729+207,529 (+356.58%)0.27%$1 MNov 13, 2026
37Bleichroeder LP236,842-500,000 (-67.86%)0.24%$1 MNov 13, 2026
38Charles Schwab Investment Management Inc204,178+39,125 (+23.70%)0.21%$1 MNov 16, 2026
39Morgan Stanley162,665-302,235 (-65.01%)0.17%$1 MNov 13, 2026
40Bank of New York Mellon Corp151,289+28,810 (+23.52%)0.16%$1 MNov 5, 2026
41Informed Momentum Co LLC145,687New0.15%$1 MNov 16, 2026
42Two Sigma Investments, LP133,632-120,330 (-47.38%)0.14%$1 MNov 16, 2026
43FMR LLC129,404+129,262 (+91029.58%)0.13%$1 MNov 10, 2026
44Creative Planning128,869+503 (+0.39%)0.13%$1 MNov 2, 2026
45AQR Capital Management LLC120,630New0.12%$1 MNov 16, 2026
46Texas Capital Bank Wealth Management Services Inc117,000-5,529 (-4.51%)0.12%$1 MNov 9, 2026
47Nuveen, LLC115,361+44,018 (+61.70%)0.12%$1 MNov 10, 2026
48Bank Of America Corp /de/108,949+53,944 (+98.07%)0.11%$1 MNov 16, 2026
49SEI Investments Co105,414New0.11%$1 MNov 10, 2026
50Stonepine Capital Management, LLC98,147-2,571 (-2.55%)0.10%$0 MNov 13, 2026
51Citigroup Inc81,718+51,626 (+171.56%)0.08%$0 MNov 4, 2026
52Rhumbline Advisers69,919+18,455 (+35.86%)0.07%$0 MNov 10, 2026
53Palogic Value Management, L.P.65,088-65,088 (-50.00%)0.07%$0 MNov 16, 2026
54Vanguard Global Advisers, LLC64,274+49,932 (+348.15%)0.07%$0 MNov 13, 2026
55Invesco Ltd.63,230+9,999 (+18.78%)0.07%$0 MNov 12, 2026
56Regency Capital Management Inc.\DE61,000+3,000 (+5.17%)0.06%$0 MNov 9, 2026
57Deutsche Bank AG\59,638+6,326 (+11.87%)0.06%$0 MNov 6, 2026
58Price T Rowe Associates Inc /MD/57,389+13,452 (+30.62%)0.06%$0 MNov 16, 2026
59Quadrature Capital Ltd41,661-4,728 (-10.19%)0.04%$0 MNov 13, 2026
60Jpmorgan Chase & Co40,507+18,308 (+82.47%)0.04%$0 MNov 12, 2026
61MetLife Investment Management, LLC40,081+7,873 (+24.44%)0.04%$0 MNov 16, 2026
62Corient Private Wealth LP37,624New0.04%$0 MNov 16, 2026
63Simplex Trading, LLC36,204+10,651 (+41.68%)0.04%$0 MNov 4, 2026
64MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.33,293+8,636 (+35.02%)0.03%$0 MNov 16, 2026
65Barclays PLC32,160+18,803 (+140.77%)0.03%$0 MNov 6, 2026
66Captrust Financial Advisors32,142+142 (+0.44%)0.03%$0 MNov 12, 2026
67Miller Financial Services LLC30,000+3,000 (+11.11%)0.03%$0 MOct 20, 2026
68Alliancebernstein L.P.25,3800 (0.00%)0.03%$0 MNov 16, 2026
69Wells Fargo & Company/mn24,936-27,697 (-52.62%)0.03%$0 MNov 16, 2026
70HighTower Advisors, LLC20,500New0.02%$0 MNov 10, 2026
71Police & Firemen's Retirement System of New Jersey19,792+3,999 (+25.32%)0.02%$0 MNov 9, 2026
72Empirical Financial Services, LLC d.b.a. Empirical Wealth Management19,649New0.02%$0 MOct 27, 2026
73Manufacturers Life Insurance Company, The19,205+3,256 (+20.42%)0.02%$0 MNov 13, 2026
74Raymond James Financial Inc16,997+1,989 (+13.25%)0.02%$0 MNov 12, 2026
75BNP Paribas Financial Markets16,981+8,800 (+107.57%)0.02%$0 MNov 12, 2026
76NewEdge Advisors, LLC16,562+198 (+1.21%)0.02%$0 MNov 13, 2026
77James Investment Research, Inc.16,3640 (0.00%)0.02%$0 MOct 22, 2026
78StoneX Group Inc.15,775New0.02%$0 MNov 3, 2026
79Centiva Capital, LP14,642New0.02%$0 MNov 13, 2026
80New York State Common Retirement Fund14,5000 (0.00%)0.01%$0 MNov 17, 2026
81Axq Capital, LP13,507New0.01%$0 MNov 12, 2026
82Voya Investment Management LLC13,242+2,225 (+20.20%)0.01%$0 MNov 10, 2026
83StoneRidge PMG Advisors, LLC12,695—0.01%$0 MNov 4, 2026
84Stokes Family Office, LLC12,1200 (0.00%)0.01%$0 MNov 12, 2026
85Sanders Morris Harris LLC12,000New0.01%$0 MOct 14, 2026
86Osaic Holdings, Inc.11,900-2,000 (-14.39%)0.01%$0 MNov 12, 2026
87First City Capital Management, Inc.11,8360 (0.00%)0.01%$0 MOct 27, 2026
88Concurrent Investment Advisors, LLC10,002New0.01%$0 MOct 16, 2026
89Annandale Capital, LLC10,0000 (0.00%)0.01%$0 MNov 18, 2026
90Seven Fleet Capital Management LP10,000-133,137 (-93.01%)0.01%$0 MNov 16, 2026
91Carolina Wealth Management Inc10,0000 (0.00%)0.01%$0 MOct 29, 2026
92Legal & General Group Plc6,544+1,341 (+25.77%)0.01%$0 MNov 16, 2026
93State of Wyoming6,262-9,642 (-60.63%)0.01%$0 MOct 28, 2026
94Ameritas Investment Partners, Inc.6,205+1,345 (+27.67%)0.01%$0 MNov 13, 2026
95Hilton Head Capital Partners, LLC4,4720 (0.00%)0.00%$0 MOct 23, 2026
96Royal Bank Of Canada4,417+2,322 (+110.84%)0.00%$0 MNov 16, 2026
97Russell Investments Group, Ltd.4,310+28 (+0.65%)0.00%$0 MNov 6, 2026
98Farther Finance Advisors, LLC4,282+792 (+22.69%)0.00%$0 MOct 8, 2026
99Quarry LP2,988+2,486 (+495.22%)0.00%$0 MNov 16, 2026
100Sterling Capital Management LLC2,296+2,108 (+1121.28%)0.00%$0 MOct 22, 2026

All 114 institutional investors, with who bought and sold →

Mutual funds holding Opus Genetics, Inc.#

49 funds hold shares worth $28 M (about 7.0% of the company). Since their previous reports 43 added shares and 3 sold, buying $16 M net.
Mutual funds holding Opus Genetics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.24 M$9 M2.3%<0.01%+18%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.35 M$6 M1.4%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.652,278$3 M0.67%<0.01%+38%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC583,651$2 M0.60%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors502,884$2 M0.52%0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC224,377$1 M0.23%<0.01%−2.1%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors179,782$1 M0.19%0.05%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.130,041$0 M0.13%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC95,002$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC100,099$0 M0.10%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC66,810$0 M0.07%<0.01%−2.2%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC71,343$0 M0.07%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC58,411$0 M0.06%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC49,881$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC45,672$0 M0.05%<0.01%+53%May 31, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers42,065$0 M0.04%0.01%no changeJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation40,000$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.34,934$0 M0.04%<0.01%+33%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.32,083$0 M0.03%<0.01%−16%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.35,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.24,866$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.23,200$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC25,597$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC20,525$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC18,264$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC15,485$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS12,142$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC12,072$0 M0.01%0.02%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC11,996$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,817$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC8,460$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC8,460$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.8,420$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC8,183$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.8,074$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC7,308$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,884$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.7,624$0 M<0.01%<0.01%+28%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC6,271$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC4,954$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,860$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS4,814$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,282$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,133$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC4,095$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,621$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,850$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,352$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,261$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.13,673$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC5,723$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC621$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 52 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Opus Genetics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$324 K
2 purchases, 1 insider
Sold, 12 months
$19.7 M
24 sales, 7 insiders
Net, 12 months
-$19.4 M
open market only
Insiders on file
32
since
$324 K-$8.6 M$0Mar 2024: bought $74 K (3 trades), sold $0 (0 trades)Mar 24May 2024: bought $15 K (2 trades), sold $0 (0 trades)Nov 2024: bought $111 K (3 trades), sold $0 (0 trades)NovDec 2024: bought $98 K (1 trades), sold $0 (0 trades)Dec 2025: bought $324 K (2 trades), sold $8.6 M (1 trades)DecMar 2026: bought $0 (0 trades), sold $181 K (4 trades)Apr 2026: bought $0 (0 trades), sold $202 K (6 trades)AprMay 2026: bought $0 (0 trades), sold $7.4 M (1 trades)Jul 2026: bought $0 (0 trades), sold $87 K (4 trades)JulSep 2026: bought $0 (0 trades), sold $2.9 M (2 trades)Oct 2026: bought $0 (0 trades), sold $218 K (5 trades)OctNov 2026: bought $0 (0 trades), sold $110 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Opus Genetics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed George MagrathChief Executive Officer, DirectorSell-28,258$3.899$110 K2.01 MForm 4
filed Joseph K. SchachleChief Operating OfficerSell-4,767$3.565$17 K286,673Form 4
filed George MagrathChief Executive Officer, DirectorSell-9,591$3.585$34 K2.04 MForm 4
filed Robert E. GagnonChief Financial OfficerSell10b5-1 plan-14,000$3.546$50 K542,375Form 4
filed Benjamin R. YerxaPresident, DirectorSell-7,669$3.551$27 K696,437Form 4
filed Benjamin R. YerxaPresident, DirectorSell-25,520$3.532$90 K670,917Form 4
filed Foundation Fighting Blindness Retinal Degeneration FundDirectorSell-556,000$4.957$2.8 M3.24 MForm 4
filed George MagrathChief Executive Officer, DirectorOption exercise+392,157$1.150$451 K2.12 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Opus Genetics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
10.9 M
15.5% of shares · 8.38 days to cover
Buybacks, Q1 2014
$0M
Q1 2014
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1.057-for-1 split in the period to ; 1.057-for-1 split ; 1-for-12.05 reverse split ; 1-for-10 reverse split

Opus Genetics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2014Q1 2014$0M
Q4 2013Q4 2013$0M
Q3 2013Q3 2013$0M
Q2 2013Q2 2013$0M
Q1 2013Q1 2013$0M
Q4 2012Q4 2012$0M
Q3 2012Q3 2012$0M
Q2 2012Q2 2012$0M
Q1 2012Q1 2012$0M
Q4 2011Q4 2011$0M
Q3 2011Q3 2011$0M
Q2 2011Q2 2011$0M
Q1 2011Q1 2012$0M
Q4 2010Q4 2011$0M
Q3 2010Q3 2011$0M

Trading halts

  • 2025-06-02 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 179 shares at $4.10
  • : 99 shares at $4.24
  • : 99 shares at $4.64
  • : 4,650 shares at $4.96
  • : 3,515 shares at $4.76

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Opus Genetics, Inc. scorecard#

Passes 4 of the 21 checks that could be worked out: strongest in financial health (3 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 15, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median25.8×Price to book 25.8× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median50.0×Price to sales 50.0× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-1.7%Free cash flow is -1.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 5
    • ✓Revenue grew in the newest year29.2%Revenue up 29.2% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-29.1%-29.1% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-29.1%-29.1% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.80 vs -2.15Diluted EPS -0.80 in fiscal 2025 against -2.15 the year before (report's currency).
    • ✗Net income higher than five years earlier-$50 M-$50 M in fiscal 2025 against -$25 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$50 MNet income -$50 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-271.8%-271.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-449.4%-449.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-271.8%-271.8% in fiscal 2025 against 45.7% in 2022.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities6.4×Current ratio 6.43 at the end of fiscal 2025.
    • ✓Debt below equity0.1×Debt to equity 0.07 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $44 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone0.31Z-score 0.31 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year132.9%Diluted shares up 132.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Opus Genetics, Inc.'s statements, beside the median of Biotechnology.

Opus Genetics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-271.8%-60.5%
Net margin-349.2%-68.9%
Return on equity-449.4%-61.0%
Revenue growth, 3 years a year-29.1%12.9%
Revenue growth29.2%15.8%
Debt to equity0.07×0.26×

3of 8on the Piotroski tests of financial strength

  • Net loss of $50 million, the 3th loss-making year in a row.
  • The share count rose 132.9% in the year.
  • More cash than debt: net cash of $44 million.

Opus Genetics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Opus Genetics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue141119400.603.0———
Research and development31271814156.65.5131110
General and administrative2218127.38.12.81.8r7.46.66.3
Operating expenses5373302223204.2r211716
Operating income−39−62−1118−23−20−4.2r−21−17−16
Interest and finance income——————0.30.30.20.1
Interest expense and finance costs0.1000.00.06.81.4———
Other non-operating income (expense)2.04.51.8−0.0−0.20.02.66.2−7.97.1
Income before tax−50−58−10.018−57−25−6.2———
Income tax000.00.3000———
Net income attributable to shareholders−50−58−10.018−57−25−6.2r−14−25−9.3
Earnings per share, basic-0.80-2.15-0.460.90-3.82-5.28-2.17r-5.25r-0.92-0.43r
Earnings per share, diluted-0.80-2.15-0.460.87-3.82-5.28-2.17r-5.25r-0.92-0.43r
Shares, weighted average (basic)62272220154.7————
Shares, weighted average (diluted)62272221154.72.8r2.7r2722r
Balance sheet
Cash and cash equivalents4530514325161.5r8.78.912
Short-term investments00.00.00.00.20————
Receivables2.03.60.91.300————
Other current assets1.80.50.10.10.10.00.0r0.60.50.4
Current assets5037544926181.8r162821
Property, plant and equipment0.20.300.00.00.00.0r0.10.10.1
Right-of-use (leased) assets——————0.2———
Total assets5037544926181.8r162821
Accounts payable3.33.12.21.11.61.20.3r3.23.21.9
Current liabilities7.8114.02.83.93.29.3r3.2——
Long-term debt1.10————————
Lease liabilities (non-current)——————0.1———
Total liabilities35114.02.83.9319.3r5.5124.0
Retained earnings−189−139−81−71−89−33−8.1r−155−140−115
Shareholders' equity156.7504622−13−7.6r−1.7r1717
Total liabilities and equity5037544926181.8r162821
Shares outstanding7032242119112.9r3.1r3224r
Cash-flow statement
Depreciation and amortization——————0.00.00.00.0
Share-based compensation3.43.43.51.81.91.50.3r1.21.01.4
Cash from operating activities−35−26−1.114−19−6.8−3.6r−19−15−13
Capital expenditure—————0−0.0———
Cash from investing activities01.200−0.10.5−0.0r12−9.44.5
Shares issued5.84.59.24.42807.76.917—
Cash from financing activities504.29.03.828214.7r6.82210
Change in cash———————−0.2−2.71.4
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Opus Genetics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.5 M
Dr. McGrath
Other top executives, average
$742 K
the CEO earned 2× this
$100 invested is now
$57
Opus Genetics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. McGrath$1.5 M$2.5 M$742 K$57
2024Dr. McGrath$889 K−$822 K$1.3 M$34
2023Chief executive$2.8 M$766 K$894 K$85

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Opus Genetics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 5 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 8

Opus Genetics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
New debt8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share saleBylaws or fiscal year changedResults announced8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Unregistered share sale8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Opus Genetics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$26 MPrivate placement after listing$10 to $50 million11equitySEC
Nov 2020$21 MPrivate placement after listing$10 to $50 million18equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Government contracts: Opus Genetics, Inc.#

No federal contracts in fiscal 2025, and $837 K in grants.

Contracts, FY2025
$0
Grants, FY2025
$837 K
FY2027 to date
—
contracts and grants
Since FY2008
$1.7 M
contracts and grants
Opus Genetics, Inc.: federal obligations by fiscal year
Fiscal yearContractsGrants
FY2025$0$837 K
FY2024$0$883 K

Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Opus Genetics, Inc.: OPUS GENETICS INC. (UEI YD2GB4S983V9)

Lobbying by Opus Genetics, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$0
#1,550 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$45 K

Lobbying firms hired in 2025

JEFFREY J. KIMBELL & ASSOCIATES, INC.

Opus Genetics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$45 K—3
2025$0—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Opus Genetics, Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Opus Genetics, Inc. compares in Biotechnology

  • Market cap$396 M · higher than 55% of 726
  • Revenue$14 M · higher than 47% of 647
  • Revenue growth29.2% · higher than 66% of 438
  • Price / sales50.0× · lower than 18% of 339
  • Price / book25.8× · lower than 7% of 534
  • FCF yield-1.7% · higher than 83% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Opus Genetics, Inc.🇺🇸$396 M——+29.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 15, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Opus Genetics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Opus Genetics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Opus Genetics, Inc.? Suggest a correction